Oncology Pipeline

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

IDH1/2 Inhibitor

LY3410738

Type of Alteration(s)

Point Mutations

Alteration(s) of Interest^*^*

IDH1 R132C/L/G/S/H
IDH2 R172K/M/G/W

Methodology

Key Considerations

NGS (Tissue)

Suitable for broad-based genomic profiling that includes targets in addition to IDH1/IDH2
Able to detect all possible IDH1/IDH2 mutations
Detection may require higher tumor content than PCR-based assays

PCR-based

Will detect selected mutations but may miss novel IDH1/IDH2 alterations

NGS (cfDNA)

Useful when tissue biopsy sample is limited/unavailable
Higher false negative rate than tissue-based NGS testing

Sanger Sequencing

Able to detect all possible IDH1/IDH2 mutations within an exon
Detection may require higher tumor content than PCR-based assays

IDH1 mutations more common than IDH2 mutations in CCA

References

1. Boscoe AN et al. J Gastrointest Oncol. 2019;10(4) 2. Yang H et al. Clin Cancer Res. 2012;18(20)

Type of Alteration(s)

Point mutations

Alteration(s) of Interest^*

IDH1 R132H/C/S/G
IDH2 R140Q/K

Methodology

Key Considerations

NGS (Blood/Marrow)

Suitable for broad-based genomic profiling that includes targets in addition to IDH1/IDH2

PCR-based

Will detect selected mutations but may miss novel IDH1/IDH2 alterations

Sanger Sequencing

Detection may require higher tumor content than PCR-based assays
Able to detect all possible IDH mutations within an exon

IDH1 and IDH2 mutations present in roughly equal proportion of AML cases

References

1. Yang H et al. Clin Cancer Res. 2012;18(20)

Check Clinical Trials information to see if patient qualifies

Need additional information or have a question:

Medical Science Liaison Request

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.